| 299 | 1 | 155 |
| 下载次数 | 被引频次 | 阅读次数 |
股骨头缺血性坏死（ANFH）是由于血供不足导致股骨头骨组织死亡的疾病，会引起髋关节疼痛和功能障碍，严重损害患者运动功能。ANFH的病理生理包括血供不足导致的骨细胞缺氧、骨代谢失衡、细胞凋亡及炎症反应，早期基本无症状，晚期常表现为关节功能严重受损。目前，ANFH采取保守治疗和手术干预均存在局限性，如效果不佳和复发风险等。血管化骨类器官作为一种新兴治疗手段，模拟股骨头微环境，增强血管生成，促进骨细胞再生，从而有效应对早期ANFH，是更具针对性的干预方案。为进一步推动血管化骨类器官技术发展和临床转化研究，本文就ANFH治疗面临的挑战、血管化骨类器官构建策略以及血管化骨类器官在ANFH修复中的应用潜力进行阐述，以期为相关领域的科研和临床工作者提供参考和启发，加速这一新兴技术的创新突破和转化应用，从而造福更多早期ANFH患者。
Abstract：Avascular necrosis of femoral head(ANFH) refers to the death of bone tissue in the femoral head due to insufficient blood supply, leading to hip joint pain and dysfunction, severely impairing patients' mobility. The pathophysiology of ANFH includes osteocyte hypoxia caused by insufficient blood supply, imbalance of bone metabolism, apoptosis, and inflammatory response. It is asymptomatic in the early stage, and often manifests as severe joint function impairment in the late stage. Currently, both conservative treatments and surgical interventions for ANFH have limitations, such as poor efficacy and risk of recurrence. As an emerging therapeutic approach, vascularized bone organoid technology simulates the microenvironment of the femoral head, enhances angiogenesis, and promotes osteocyte regeneration, thereby effectively addressing early-stage ANFH and offering a more targeted intervention strategy. To further advance the development of vascularized bone organoid technology and drive its clinical translational research, this article discusses the challenges in ANFH treatment, the construction strategies of vascularized bone organoids, and the potential applications of this technology in ANFH repair. It aims to provide references and inspiration for researchers and clinicians in related fields, accelerating innovative breakthroughs and translational applications of vascularized bone organoid technology to ultimately benefit more patients with ANFH.
[1] Lu Y, Chen X, Lu X, et al. Reconstructing avascular necrotic femoral head through a bioactive β-TCP system:from design to application[J]. Bioact Mater, 2023, 28:495-510.
[2] Goncharov EN, Koval OA, Nikolaevich Bezuglov E, et al.Conservative treatment in avascular necrosis of the femoral head:a systematic review[J]. Med Sci(Basel), 2024, 12(3):32.
[3] Singh M, Singh B, Sharma K, et al. A molecular troika of angiogenesis, coagulopathy and endothelial dysfunction in the pathology of avascular necrosis of femoral head:a comprehensive review[J]. Cells, 2023, 12(18):2278.
[4] Howse L, Bendall S. Avascular necrosis of the femoral head:management remains controversial[J]. J Orthop Traumatol, 2023, 37(4):246-252.
[5] Sprangers J, Zaalberg IC, Maurice MM. Organoid-based modeling of intestinal development, regeneration, and repair[J]. Cell Death Differ, 2021, 28(1):95-107.
[6] Sampaziotis F, Muraro D, Tysoe OC, et al. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver[J]. Science, 2021, 371(6531):839-846.
[7] Tang XY, Wu S, Wang D, et al. Human organoids in basic research and clinical applications[J]. Signal Transduct Target Ther, 2022, 7(1):168.
[8] Wang J, Wu Y, Li G, et al. Engineering large-scale selfmineralizing bone organoids with bone matrix-inspired hydroxyapatite hybrid Bioinks[J]. Adv Mater, 2024, 36(30):2309875.
[9] Wang J, Chen X, Li R, et al. Standardization and consensus in the development and application of bone organoids[J].Theranostics, 2025, 15(2):682-706.
[10] Zhao X, Li N, Zhang Z, et al. Beyond hype:unveiling the real challenges in clinical translation of 3D printed bone scaffolds and the fresh prospects of bioprinted organoids[J]. J Nanobiotechnology, 2024, 22(1):500.
[11] Murab S, Hawk T, Snyder A, et al. Tissue engineering strategies for treating avascular necrosis of the femoral head[J].Bioengineering(Basel), 2021, 8(12):200.
[12] Konarski W, Pobo?y T,?liwczyński A, et al. Avascular necrosis of femoral head-overview and current state of the art[J]. Int J Environ Res Public Health, 2022, 19(12):7348.
[13] Ma T, Wang Y, Ma J, et al. Research progress in the pathogenesis of hormone-induced femoral head necrosis based on microvessels:a systematic review[J]. J Orthop Surg Res,2024, 19(1):265.
[14] Tencerova M, Kassem M. The bone marrow-derived stromal cells:commitment and regulation of adipogenesis[J].Front Endocrinol(Lausanne), 2016, 7:127.
[15] Lou Y, Wu J, Zhong Y, et al. Etiology, pathology, and treatment of osteonecrosis of the femoral head in adolescents:a comprehensive review[J]. Medicine(Baltimore), 2024, 103(30):e39102.
[16] Duan P, Wang H, Yi X, et al. C/EBPα regulates the fate of bone marrow mesenchymal stem cells and steroid-induced avascular necrosis of the femoral head by targeting the PPARγ signalling pathway[J]. Stem Cell Res Ther, 2022, 13(1):342.
[17] Goncharov EN, Koval OA, Nikolaevich Bezuglov E, et al.Conservative treatment in avascular necrosis of the femoral head:a systematic review[J]. Med Sci(Basel), 2024, 12(3):32.
[18]中国医师协会骨科医师分会骨循环与骨坏死专业委员会,中华医学会骨科分会骨显微修复学组,国际骨循环学会中国区.中国成人股骨头坏死临床诊疗指南(2020)[J].中华骨科杂志, 2020, 40(20):1365-1376.
[19] Mont MA, Salem HS, Piuzzi NS, et al. Nontraumatic osteonecrosis of the femoral head:where do we stand today?:a5-year update[J]. J Bone Joint Surg Am, 2020, 102(12):1084-1099.
[20] Zhang Y, Wang X, Jiang C, et al. Biomechanical research of medial femoral circumflex vascularized bone-grafting in the treatment of early-to-mid osteonecrosis of the femoral head:a finite element analysis[J]. J Orthop Surg Res, 2022,17(1):441.
[21] Ackerman IN, Bennell KL, Osborne RH. Decline in healthrelated quality of life reported by more than half of those waiting for joint replacement surgery:a prospective cohort study[J]. BMC Musculoskelet Disord, 2011, 12:108.
[22] Li M, Ma Y, Fu G, et al. 10-year follow-up results of the prospective, double-blinded, randomized, controlled study on autologous bone marrow buffy coat grafting combined with core decompression in patients with avascular necrosis of the femoral head[J]. Stem Cell Res Ther, 2020, 11(1):287.
[23] Lou P, Zhou G, Wei B, et al. Bone grafting for femoral head necrosis in the past decade:a systematic review and network meta-analysis[J]. Int J Surg, 2023, 109(3):412-418.
[24] Quaranta M, Miranda L, Oliva F, et al. Osteotomies for avascular necrosis of the femoral head[J]. Br Med Bull,2021, 137(1):98-111.
[25] Maruyama M, Moeinzadeh S, Guzman RA, et al. The efficacy of lapine preconditioned or genetically modified IL4over-expressing bone marrow-derived mesenchymal stromal cells in corticosteroid-associated osteonecrosis of the femoral head in rabbits[J]. Biomaterials, 2021, 275:120972.
[26] Zhao Y, Li S, Feng M, et al. Effects of puerarin-loaded tetrahedral framework nucleic acids on osteonecrosis of the femoral head[J]. Small, 2023, 19(41):2302326.
[27] Aarvold A, Smith JO, Tayton ER, et al. A tissue engineering strategy for the treatment of avascular necrosis of the femoral head[J]. Surgeon, 2013, 11(6):319-325.
[28] Zhao D, Saiding Q, Li Y, et al. Bone organoids:recent advances and future challenges[J]. Adv Healthc Mater, 2024,13(5):2302088.
[29] Salewskij K, Penninger JM. Blood vessel organoids for development and disease[J]. Circ Res, 2023, 132(4):498-510.
[30]王健,白龙,陈晓,等.骨类器官的构建、评价与应用专家共识(2024版)[J].中华创伤杂志, 2024, 40(11):974-986.
[31] Wang J, Zhou D, Li R, et al. Protocol for engineering bone organoids from mesenchymal stem cells[J]. Bioact Mater,2025, 45:388-400.
[32] Mansour AA, Gon?alves JT, Bloyd CW, et al. An in vivo model of functional and vascularized human brain organoids[J]. Nat Biotechnol, 2018, 36(5):432-441.
[33] Salas AP, Mazek J, O'Donnell J, et al. Hip arthroscopy and core decompression for avascular necrosis of the femoral head using a specific aiming guide:a step-by-step surgical technique[J]. Arthrosc Tech, 2021, 10(12):e2775-e2782.
[34] Ji Q, Li X, Luo S, et al. Long-term outcomes of arthroscopic synovectomy and core decompression through multiple small bone holes for early-stage avascular necrosis of the femoral head[J]. Arthroplasty, 2023, 5(1):17.
[35] Wimmer RA, Leopoldi A, Aichinger M, et al. Human blood vessel organoids as a model of diabetic vasculopathy[J].Nature, 2019, 565(7740):505-510.
[36] Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders[J]. Nat Rev Neurol, 2018, 14(3):133-150.
[37] Kim JW, Nam SA, Yi J, et al. Kidney decellularized extracellular matrix enhanced the vascularization and maturation of human kidney organoids[J]. Adv Sci(Weinh), 2022, 9(15):e2103526.
[38] Garreta E, Moya-Rull D, Marco A, et al. Natural hydrogels support kidney organoid generation and promote in vitro angiogenesis[J]. Adv Mater, 2024, 36(34):2400306.
[39] Low JH, Li P, Chew EGY, et al. Generation of human PSCderived kidney organoids with patterned nephron segments and a de novo vascular network[J]. Cell Stem Cell, 2019, 25(3):373-387. e9.
[40] Dao L, You Z, Lu L, et al. Modeling blood-brain barrier formation and cerebral cavernous malformations in human PSC-derived organoids[J]. Cell Stem Cell, 2024, 31(6):818-833. e11.
[41] Carolina E, Kuse Y, Okumura A, et al. Generation of human iPSC-derived 3D bile duct within liver organoid by incorporating human iPSC-derived blood vessel[J]. Nat Commun, 2024, 15(1):7424.
[42] Homan KA, Gupta N, Kroll KT, et al. Flow-enhanced vascularization and maturation of kidney organoids in vitro[J].Nat Methods, 2019, 16(3):255-262.
基本信息:
中图分类号:R681.8
引用信息:
[1]王健,白龙,陈晓,等.血管化骨类器官修复早期股骨头缺血性坏死策略[J].中华骨与关节外科杂志,2025,18(03):193-199.
基金信息:
国家自然科学基金（82230071）; 上海申康医院发展中心研究型医师创新转化能力培训项目（SHDC2023CRT013）; 上海市创新医疗器械应用示范项目（23SHS05700-01）